Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

Medicare Retail Drug Spending Accelerates In 2018 Despite Price Declines

Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.

Medicare Pricing Debate

HHS Will Take Anti-Kickback Safe Harbor Proposals For Drug Contracting ‘Seriously,’ US Official Promises

Health and Human Services Department Deputy Secretary Eric Hargan invites biopharma companies to submit proposals on how to modify or create safe harbors that would be suitable for innovative reimbursement contracts involving prescription drugs.

Reimbursement Medicare

Real World Evidence For Rare Diseases: Payers Cite Lack Of Clarity On Value

Survey of US and European payers suggests manufacturers should 'leverage' key opinion leaders trusted by payers to help drive better understanding and acceptance of real world data.

Reimbursement Real-World Evidence

US Senate Finance Drug Pricing Bill Would Have ‘Negligible’ Impact, Analyst Predicts

Now that US drug pricing reform seems inevitable, the Senate bill offers the most positive outcome for industry, Bernstein analyst Ronny Gal suggests. 

Pricing Debate Legislation

Co-Pay Charity Settles Charges It Conspired With Teva, Biogen, Novartis On Kickbacks

The Assistance Fund directed donations received from the companies to patients taking their multiple sclerosis drugs, the US Department of Justice announced. Further settlements may be pending.

Compliance Legal Issues

Medicare Add-On Payments For New Dialysis Drugs Limited To ‘Innovative’ Products

Centers for Medicare and Medicaid Services narrows the types of drugs eligible for add-on payments in the Medicare end-stage renal program as it tries to balance efforts to promote innovation with controlling costs.

Reimbursement Renal
See All
UsernamePublicRestriction

Register